Overview


According to FutureWise analysis the market for Rheumatoid Arthritis Drugs in 2023 is US$ 65.22 billion, and is expected to reach US$ 82.74 billion by 2031 at a CAGR of 3.00%.

FutureWise Market Research has offered an in-depth analysis on the Rheumatoid Arthritis Drugs Market. It provides a detailed synopsis of rheumatoid arthritis drugs market trends affecting the market growth. Additionally, this report offers region-wise proliferation and the graph of profitability, instrumental information pertaining to the rheumatoid arthritis drugs market share and SWOT analysis of this market. Moreover, this report provides the current market position of key market players in the competitive analysis of rheumatoid arthritis drugs market, while inflating their corporate strategies and provision of products.

The rheumatoid arthritis drugs market is predicted to achieve a substantial growth rate over the forecast timeframe as per the research study. The report further illustrates that this business is anticipated to register significant market numbers during the forecast period. Furthermore, this report offers key insights regarding the current overall industry valuation and it mentions the segmentation of the rheumatoid arthritis drugs market coupled with the profitable opportunities for the growth across this business vertical.
  • Abbvie
  • Biogen Inc.
  • Bristol-Myers Squibb
  • Celgene Corp.
  • Celltrion Inc.
  • Johnson & Johnson
  • Medimmune LLC
  • MerckCo. Inc.
  • Novartis International AG
  • Takeda Pharmaceutical Co. Ltd.

By Therapeutic Molecule

  • Pharmaceuticals
    • NSAIDs
    • Analgesics
    • DMARDs
    • Corticosteroids
  • Biopharmaceuticals
    • Biologics
    • Biosimilars

By Route of Administration

  • Oral
  • Parenteral

By Sales Channel

  • Prescription
  • Over-the-counter (OTC)

By Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East and Africa
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the rheumatoid arthritis drugs market by therapeutic molecule, by route of administration, by sales channel and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, industry-specific restraints and opportunities)
  • To forecast and evaluate micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East Africa
  • To record, evaluate and analyse competitive landscape mapping- technological advancements, product launches, expansions and mergers
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization services offered are free of charge with purchase of any license of the report.
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Global Rheumatoid Arthritis Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Global Rheumatoid Arthritis Drugs Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Rheumatoid Arthritis Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Global Rheumatoid Arthritis Drugs Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Global Rheumatoid Arthritis Drugs Market, By Therapeutic Molecule Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pharmaceuticals
         1.1. NSAIDs
         1.2. Analgesics
         1.3. DMARDs
         1.4. Corticosteroids
        2. Biopharmaceuticals
         2.1. Biologics
         2.2. Biosimilars

  • 8.   Global Rheumatoid Arthritis Drugs Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Oral
        2. Parenteral

  • 9.   Global Rheumatoid Arthritis Drugs Market, By Sales Channel Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Prescription
        2. Over-the-counter (OTC)

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Venezuela
         3.3. Argentina
         3.4. Rest of Latin America
        4. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Switzerland
         2.9. Rest of Western Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. Singapore
         2.4. India
         2.5. Australia and New Zealand
         2.6. ASEAN
         2.7. South Korea
         2.8. Taiwan
         2.9. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape

    •        1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Connected Devices and Disease Indication Portfolio, Financial Layouts)

    •   1. Abbvie
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Biogen Inc.
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Bristol-Myers Squibb
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Celgene Corp.
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Celltrion Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson & Johnson
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. Medimmune LLC
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. MerckCo. Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Novartis International AG
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10.Takeda Pharmaceutical Co. Ltd.
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact

    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by
      administrations
        5. The overall economic slowdown of the developing and developed nations

  • 18.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11